Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Combining medical knowledge to save lives

10.07.2008
European researchers hope to gain more insight into cardiovascular disease by combining clinical, laboratory and metabolic records with genomic data

Cardiovascular disease (CVD) is the biggest killer among chronic diseases, claiming 17 million lives globally every year. Yet doctors can only attribute 50% of cardiovascular diseases to known risk factors.

Understanding the other risk factors would help doctors target their treatments more accurately, possibly helping to save more lives. A better understanding might also mean individuals could take a more focused effort to reduce their risk of developing a CVD condition.

Many of the risk factors for CVDs, like smoking, gender and low-density lipoprotein (LDL) cholesterol, are well known. But CVD is a complex condition, with very wide variations among the population. By gaining an increased understanding of the risk parameters, doctors would be in a better position to identify those more at risk of CVD.

Enter Multi-Knowledge, an EU-funded project that has developed an IT platform that can combine clinical, laboratory and metabolic information with high throughput genomic data about the same individual.

Other studies have combined genomic data with clinical data, but the Multi-Knowledge team did that exercise on a much larger scale, says Dr. Zohar Yakhini, the project’s technical coordinator.

“People normally collect clinical data that they are interested in, while we have just collected data from a cohort that consists of mostly nominally healthy people,” Yakhini says. “The clinical data that we are working with is much richer than we have seen in the past, that is a novelty of the project.”

By combining information in this way, doctors and researchers will be able to analyse the correlation between the gene expression profile in the blood of an individual and their risk of developing CVD.

“We find pre-clinical conditions to be associated to certain genomic signatures in this population,” he says. “This means that disease processes that start early might already manifest themselves in the genomic data.”

For example, doctors could use the information to identify blood gene expression signatures that link smoking and CVD in some patients, and cholesterol and CVD in others.

If achieved, this level of understanding would provide a powerful tool in preventative medical care. Simple lifestyle changes could reduce an individual patient’s risk of developing a cardiovascular disease to almost zero.

How it works
The Multi-Knowledge system works by combining heterogeneous data into a single computing platform. It sounds simple, but the task was complex.

Gene and protein expression analysis is a very data intensive application. Gene expression occurs when information encoded in DNA gets converted into structures present and operating in a cell. These are the mRNA molecules.

Expression profiling of those molecules, using microarrays, produces very large quantities of information that can be difficult for non-specialists to analyse.

The Multi-Knowledge team developed a data collection system and the protocols to combine the data with additional information collected in a distributed set-up. In this respect the project will have an important influence on emerging standards for heterogeneous medical data collection.

The data, which can come from many sources and take many forms, is stored in a data repository that houses both raw information as well as analysis results. All participants in the study can access data and use the analysis tools that are part of the system. The data analysis tools allow users to connect the repository with external databases and annotations.

After all this work in the background, the information is presented to users via a portal. The platform is an elegant approach to combining various forms of medical data, but its relevance to the clinic depends on its usefulness.

Testing times
So the Multi-Knowledge team tested the new platform by using it to study CVD risk factors in a nominally healthy sample. One such well-known risk is smoking. The Multi-Knowledge team therefore tested this well-known risk factor in 50 apparently healthy young adults. They were looking for an over-expression of genes that provoked an inflammatory response.

The system passed with flying colours. There was a clear over expression of genes that provoke an inflammatory response in those patients who smoked. The team also identified distinct inflammatory expression genetic signatures for smoking and for other risk factors, such as high LDL cholesterol.

The project, which received funding from the EU's Sixth Framework Programme for research, finishes at the end of June 2008. Team members currently continue to work on various elements of the system.

“Not all elements of the system are integrated together, so we are working on that,” says Yakhini. “Other elements of the system have already been deployed in several sites, like the data analysis tool.”

Ultimately the developments will influence the various new approaches to medical information taken by the consortium partners.

“From a commercial perspective, we are not necessarily going to develop a full commercial system,” says Yakhini. “It will likely be the case that respective partners will take pieces of this work and incorporate it into other products that they already have. From an industry standpoint this is also a favourable result.

“But I think many of the consortium partners will continue to work together after the lifetime of the project, finding more pieces in the puzzle that will ultimately yield effective diagnoses tools combining clinical and genomic analysis.”

And then the final impact will be lives saved through better prevention of cardiovascular disease.

Cardiovascular disease is the number one cause of death globally. An estimated 17.5 million people died from cardiovascular disease in 2005, representing 30% of all deaths, according to the World Health Organisation (WHO). Of these deaths, 7.6 million were due to heart attacks and 5.7 million were due to stroke.

By comparison diabetes is responsible for the deaths of one million people.

Cardiovascular disease is caused by disorders of the heart and blood vessels, and includes coronary heart disease (heart attacks), cerebrovascular disease (stroke), raised blood pressure (hypertension), peripheral artery disease, rheumatic heart disease, congenital heart disease and heart failure.

The major causes of cardiovascular disease are tobacco use, physical inactivity, and an unhealthy diet, WHO says.

Note for the media: This feature can be republished without charge provided ICT Results is acknowledged as the source at the top or the bottom of the story. You must request permission before you use any of the photographs on the site. If you do republish, we would be grateful if you could let us know so as to help us provide you with a better service. If you want further information on any of the projects cited in this story please contact us at ictresults@esn.eu.

Christian Nielsen | alfa
Further information:
http://www.esn.eu
http://cordis.europa.eu/ictresults/index.cfm/section/news/tpl/article/BrowsingType/Features/ID/89850

Further reports about: CVD Cardiovascular Medical Multi-Knowledge Yakhini combining

More articles from Life Sciences:

nachricht Unique genome architectures after fertilisation in single-cell embryos
30.03.2017 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH

nachricht Transport of molecular motors into cilia
28.03.2017 | Aarhus University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Challenging European Research Project to Develop New Tiny Microscopes

The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.

To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

'On-off switch' brings researchers a step closer to potential HIV vaccine

30.03.2017 | Health and Medicine

Penn studies find promise for innovations in liquid biopsies

30.03.2017 | Health and Medicine

An LED-based device for imaging radiation induced skin damage

30.03.2017 | Medical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>